Literature DB >> 18669758

Effect of depot medroxyprogesterone acetate on glucose tolerance in generalized lipodystrophy.

Belinda J Yauger1, Phillip Gorden, Jean Park, Elaine Cochran, Pamela Stratton.   

Abstract

BACKGROUND: Lipodystrophy is a rare condition causing severe insulin resistance and frank diabetes. Depot medroxyprogesterone acetate (DMPA), a commonly used contraceptive, may worsen glucose tolerance in diabetics and those with lipodystrophy. CASE: A young woman with generalized lipodystrophy, who previously required greater than 1,000 units of insulin daily, had a normal hemoglobin A1c on leptin and metformin only. After an injection of DMPA, she developed severe hyperglycemia. Her levels returned to near normal only with extremely high doses of insulin (up to 1,700 units/d) and increased doses of leptin and metformin.
CONCLUSION: Progestin-only contraceptives may detrimentally affect glucose tolerance, particularly in patients with lipodystrophy, a cause of severe insulin resistance and leptin deficiency. One DMPA injection appeared to profoundly alter glucose metabolism in this patient with frank diabetes resulting from lipodystrophy. The effect of progestin-only contraceptives on glucose tolerance should be monitored closely in any diabetic patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18669758      PMCID: PMC3470469          DOI: 10.1097/AOG.0b013e3181662d17

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

Review 1.  Acquired and inherited lipodystrophies.

Authors:  Abhimanyu Garg
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

Review 2.  Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction.

Authors:  Katsutaro Morino; Kitt Falk Petersen; Gerald I Shulman
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

3.  Insulin sensitivity in streptozotocin-induced diabetic rats treated with different doses of 17beta-oestradiol or progesterone.

Authors:  Patricia Ordóñez; María Moreno; Ana Alonso; Rebeca Fernández; Fernando Díaz; Celestino González
Journal:  Exp Physiol       Date:  2006-10-26       Impact factor: 2.969

4.  Effects of medroxyprogesterone acetate on serum insulin and growth hormone levels in diabetics and potential diabetics.

Authors:  H Gershberg; E Zorrilla; A Hernandez; M Hulse
Journal:  Obstet Gynecol       Date:  1969-03       Impact factor: 7.661

5.  Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration.

Authors:  M Hiroi; F Z Stanczyk; U Goebelsmann; P F Brenner; M E Lumkin; D R Mishell
Journal:  Steroids       Date:  1975-09       Impact factor: 2.668

6.  Leptin-replacement therapy for lipodystrophy.

Authors:  Elif Arioglu Oral; Vinaya Simha; Elaine Ruiz; Alexa Andewelt; Ahalya Premkumar; Peter Snell; Anthony J Wagner; Alex M DePaoli; Marc L Reitman; Simeon I Taylor; Phillip Gorden; Abhimanyu Garg
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

7.  Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.

Authors:  A Ortiz; M Hirol; F Z Stanczyk; U Goebelsmann; D R Mishell
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

Review 8.  Leptin receptor signaling and the regulation of mammalian physiology.

Authors:  Martin G Myers
Journal:  Recent Prog Horm Res       Date:  2004
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.